Kornimate/medical-research-clean huggingface dataset:
adjuvant immune checkpoint inhibitors in postoperative hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: though hepatectomy is the best treatment for patients with hepatocellular carcinoma (hcc), the 5-years recurrence-free survival is lower than 30%. in recent years, several immune checkpoint inhibitors have been approved in advanced hcc. no study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with hcc after hepatectomy was reported.

hepatic resection is the best treatment for patients with early stage hepatocellular carcinoma (hcc) or selected intermediate or advanced disease. however, the postoperative 5-years recurrent rate is up to 70%, for whom recurrence is a major cause of death. in recent years, several immune checkpoint inhibitors have been approved in advanced hcc by official guidelines. at the same time, four randomizead controlled trials about adjvuant immune checkpoint inhibitors for postoperative hcc are ongoing. however, no study about the safety and efficacy of adjuvant immune checkpoint inhibitors for such patients in clinical practice was reported. therefore, the investigators plan to investigate the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with high-risk factor of hcc recurrence after curative hepatectomy in a prospective cohort study.

Eligibility criteria:
inclusion criteria: * underwent curative hepatectomy; * diagnosis of hcc was confirmed by postoperative histopathology; * liver function child-pugh a or b; * performance status score 0 or 1 * with high risk factor of hcc recurrence, such as tumor size ≥ 5 cm, multinodular, macrovascular invasion or microvascular invasion; receive immune checkpoint inhibitors based adjuvant therapy. exclusion criteria: * receive neoadjuvant immune checkpoint inhibitors therapy.

Keywords: immune checkpoint inhibitor
analysis of the prevalence of sensitization to plants containing gibberellins using realistic skin prick tests

Conditions: Food Allergy

Summary: gibberellin-related proteins (grps) are proteins contained in both pollens and vegetables and are associated with an increased risk of severe food allergy reactions. the best characterized one the only one for which a specific ige (immunoglobulin e) may be dosed in current clinical practice is pru p 7, an allergen contained in peaches (prunus persica). sensitization to grps seems to be greater in areas with high exposure to pollens of the cupressaceae family (as in the montpellier region in southern france); a subtype of cupressaceae pollinosis, characterized by sensitization to pru p 7 has been shown to be responsible for severe peach allergies. to date, there has been no real analysis of the prevalence of sensitization to grps, or of possible cross-sensitization between plants and foods containing grps. main food containing grps with a high level of homology with pru p 7 include apples (malus domestica, 97.3%), sesame (sesamum indicum, 91.9%), carrots (daucus carota subsp. sativus, 88.9%), lemons and oranges (different species, with a homology of 87.3%). if investigators consider that sensitization to grps could be associated with severe allergic hypersensitivity reactions, it is important to detect the prevalence of sensitization to these allergens and to find sensitization profiles for these patients in order to gain a better understanding of this type of allergy and offer a more appropriate and preventive management to allergic patients. this remains today a major challenge for the allergy community in the mediterranean region. this study aims to investigate the rate of sensitization to peach and 5 other allergens containing gibberellins, chosen on the basis of their homology with pru p 7 (the gibberellin from prunus persica): carrot, lemon, orange, apple and sesame.


Eligibility criteria:
inclusion criteria: * patients aged at least 5 years * patients consulting at the allergy unit of the university hospital of montpellier for any type of allergy work-up/evaluation * oral consent from the patient and, where applicable, from at least one of the patient's legal representatives in the case of minors. exclusion criteria: * patients treated with antihistamines or psychotropic drugs with antihistaminic action during the 7 days prior to inclusion * patients with pathologies that prevent the performance of prick tests (e.g. severe peripheral neuropathy, cutaneous anergy). * patients with dermographism. * patient taking part in another study which may influence the results of the prick tests. * patients in an exclusion period determined by a previous study. * pregnant, parturient or breast-feeding women. * patients or their legal representatives under court protection, guardianship or trusteeship. * patients or their legal representatives who are not members or beneficiaries of a health insurance scheme. * patient or his/her legal representative unable to read and understand french fluently.

Keywords: gibberellins prevalence sensitization pru p 7 cross-reactions
effect of resistive exercises versus aerobic exercises on varicose veins in postmenopausal women

Conditions: Varicose Veins

Summary: the purpose of this study will be to determine the effect of resistive exercises on varicose veins in postmenopausal women, the effect of aerobic exercise on varicose veins in postmenopausal women and to compare between the effect of resistive exercise versus aerobic exercise on varicose veins in post menopausal women.

varicose veins in the lower extremities present a spectrum of symptoms from cosmetic issues to severe discomfort including telangiectases, reticular veins, edema, pigmentation, and venous ulceration. these veins lead to painful swelling, skin discoloration, and potential complications like thrombosis, and nerve injury, impacting an individual's efficiency and life quality. exercise, particularly aerobic and resistance training, has shown promise in improving pain severity, functional ability, and venous blood flow. so, the current study will be conducted to compare between the effect of resistive exercises versus aerobic exercises on varicose veins in postmenopausal women.

Eligibility criteria:
inclusion criteria: * all women suffering from varicose veins. * their age will range from 50 to 65 years. * their body mass index will range from 25 to 29.9 kg/m2. * voluntary acceptance of participation in the study. exclusion criteria: * had history of serious vascular disease as deep venous thrombosis. * sensory deficient * any dermatological condition that interferes with the procedure. * any musculoskeletal or neurological disorders. * acute or healed ulcer wounds. * any heart disease or pulmonary disease.

Keywords: resistive exercises aerobic exercises varicose veins postmenopausal women
cream containing sericin and turmeric in psoriasis patients

Conditions: Psoriasis

Summary: psoriasis lesion is divided into two parts. half of the lesion will apply cream containing sericin and turmeric and another will apply steroid cream (control). the samples will be apply two times a day for 8 weeks. psoriasis area and severity index, physician global assessment, body surface area of lesion, dermatology life quality index, itching score, adverse reaction are evaluated before, after using the samples for 4 and 8 weeks.


Eligibility criteria:
inclusion criteria: * age over 18 years * patients with body surface area of psoriasis lesion less than 10, have psoriasis area and severity index less than 10 , and no lesion at face, hands,feet, and genital area * no topical application on psoriasis lesion at least 2 weeks * willing to attend the study exclusion criteria: * uncontrolled diseases * allergic to sericin turmeric and steroid * other skin diseases * pregnancy and lactation
prediction of the response to chemotherapy by tomoscintigraphie the mibi in the balance sheet pre hodgkin's disease and lymphoma malins high grade

Conditions: Hodgkin's Disease; Malignant Lymphomas High Grade; Chemoresistance

Summary: predicting response to chemotherapy in patients with hodgkin's disease or lymphoma high-grade malignant de novo or recurrence. the non-hodgkin's lymphoma and high-grade hodgkin's disease may show resistance to chemotherapy, regardless of their initial extension. the failure of treatment is most often correlated with an incomplete answer or lack of response to chemotherapy as a result chemoresistance. this drug, which may involve the gene mdr1 (multidrug resistance) encoding the protein pgp, can be studied in vivo by mibi scan. the mibi is behind a tracer perfusionnel used routinely to explore myocardial perfusion, but it has other characteristics of fixing, which can be used in oncological imaging (fixation by glial tumors of high grade).prospective study, which includes conducting a tomoscintigraphie 30 minutes after injection of 20 mci of 99mtc-mibi in initial stock or relapse of high-grade lymphoma and hodgkin's disease any stage (i-iv). fixing the mibi is compared with morphological abnormalities detected by ct and the setting of lesions by 18fdg. patients will be treated in a traditional way, without changes in treatment protocols used in routine. patients with a negative mibi scan, will be watched with particular attention in order to detect insufficient response to chemotherapy. the only change, the care of patients, only for the achievement of an initial consideration of non-invasive imaging, further, which is the tomoscintigraphie the mibi. of the tumor samples, will be evaluated by immunohistochemistry, the expression of pgp and the mrp1 (two proteins associated with the drug). on blood, may be carried out genotyping of mdr1, mrp1 and mrp2 to the patient.


Eligibility criteria:
inclusion criteria: * initial attainment: high-grade nhl or hodgkin's disease all stages:i, ii, iii et iv. * relapse: high-grade nhl or hodgkin's disease relapse in all stages:i, ii, iii et iv. * patients recruited by the network of clinical hematology du limousin * patients older than 18 years with or without brain damage exclusion criteria: * pregnant women or nursing mothers or without effective contraception * patients without coverage by social security * patients who started steroids referred to antitumor

Keywords: hodgkin's disease malignant lymphomas high grade chemoresistance mibi pgp mrp1 tumor response
study of the effectiveness of valbenazine on patient- and clinician-reported outcomes in participants with tardive dyskinesia

Conditions: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder; Major Depressive Disorder; Tardive Dyskinesia

Summary: this study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (td) who are receiving valbenazine for up to 24 weeks.


Eligibility criteria:
key inclusion criteria: * at least 18 years of age * have one of the following clinical diagnoses: schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder * have a clinical diagnosis of neuroleptic-induced td * medication(s) for schizophrenia or schizoaffective disorder, bipolar disorder, or major depressive disorder and other protocol-allowed concurrent medications must be at a stable dose and expected to remain stable during the study * participants must be outpatients and have a stable psychiatric status key exclusion criteria: * have comorbid abnormal involuntary movement(s) (for example, parkinsonism, akathisia) that is more prominent than td * have an active, clinically significant unstable medical condition in the judgement of the investigator, or have any laboratory value outside the normal range that is considered by the investigator to be clinically significant at the screening visit
different squatting modes in the rehabilitation of patellofemoral pain syndrome

Conditions: Patellofemoral Pain Syndrome

Summary: this study take 84 patients with patellofemoral pain syndrome in peking university third hospital during january to september in 2023 as subjects, aiming to explore the efficacy and intervention effects of three different static squat modes including straight leg raise, wall squat, direct squat and wall squat assisted by elastic bands for patients with pfps, in order to providing theoretical basis and effective guidance for future home rehabilitation of patients with pfps combined with mobile health.

background：static squat has been widely used in the treatments of patellofemoral pain syndrome (pfps), but no study has assessed which static squat modes is more effective .this study aimed to compare the effects of three different static squat modes on patients with patellofemoral pain syndrome . methods：investigators included 84 patients with patellofemoral pain syndrome, a 6-week training period using a mobile phone app with angle recognition function, patients were devided into 4 groups based on different static squat modes. kujala score, lysholm score, vas-w score, vas-u score,thigh circumference, peak torque of knee extension, and peak torque of knee flexion on the affected side were used to assess efficacy.two-way anova was conducted to determine the differences within and between groups.paired-samples t-test was used for intergroup comparisons, and one-way anova was applied for intergroup comparisons. chi-square tests were performed on categorical data.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria of pfps. * age between 20 and 45 years (to reduce the risk of suffer from patellofemoral joint bone joint) * have no other treatments before the experiment. * sign the informed consent form. exclusion criteria: * patients with a history of knee surgery. * with other lower limb injuries such as meniscus tear, bursitis, ligament injury, patellar tendon injury, joint degeneration, etc. * with a history of dislocation and subluxation of patellofemoral joint. * with cardiovascular vessels, lung, kidney and other important organs. * not available to use mobile phone app

Keywords: patellofemoral pain syndrome static squat rehabilitation
study to evaluate reactogenicity and immunogenicity of revaccination with adjuvanted influenza vaccine in elderly adults

Conditions: Influenza

Summary: since influenza vaccines are normally administered every year because of the frequent change in their antigenic composition, the safety and immunogenicity profiles of the adjuvanted influenza vaccine need to be re-evaluated after repeated vaccine administration. in this study, subjects enrolled in a previous study will receive a booster dose with the 2006-2007 season's formulations of fluarix or the adjuvanted vaccine.


Eligibility criteria:
inclusion criteria: * the subjects must be healthy adults ages 18-40 years or \>/= 65 years previously vaccinated with either fluarix or the adjuvanted vaccine. exclusion criteria: * subjects will be excluded if they take/have taken chronically high doses of immunosuppressants or other immune modifying drugs within six months before vaccination, or immunoglobulins or blood products within three months before vaccination, or any investigational product within 30 days before vaccination * have a history of influenza infection since previous vaccination * women who are pregnant * subjects who have an acute or chronic clinically significant disease or an immunosuppressive/deficient condition, or have contra-indications to influenza vaccination

Keywords: influenza, improved vaccine, influenza disease elderly
bubolight®, a new phototherapy device for the treatment of the newborn's jaundice

Conditions: Neonatal Jaundice

Summary: about 50% of full-term newborns and 80% of premature infants develop jaundice which is due to hyperbilirubinemia. in the majority of cases, jaundice disappears naturally without treatment within three weeks of birth, but the bilirubin level may remain too high, which can lead to a serious neurological disease: kernicterus. to avoid this, a therapeutic management must be instituted, and in some cases, one or more phototherapy sessions (pt) may be prescribed. the aim of this trial is to evaluate the safety and level of satisfaction of parents and healthcare team with one innovative device for phototherapy bubolight® included two removable strips of luminous textile incorporating optical fibers. 10 newborns requiring phototherapy, will be illuminated during four hours in one session of pt bilirubin levels is taken at the start of phototherapy h0 and controls are made at h+6 hours.


Eligibility criteria:
inclusion criteria: * at time of birth, infant is \> 35 weeks gestation * presence of jaundice confirmed by measurement of bilirubin (transcutaneous bilirubinometer) * total bilirubinemia rate requiring phototherapy according to national institute for health and clinical excellence. * weight ≥2.500kg * judged in good health by the investigator following the clinical examination and the medical data (absence of perinatal asphyxia, antibiotic treatment, respiratory disorders) * absence of fœto-maternal rhesus incompatibility or kell exclusion criteria: * newborn already treated with phototherapy * febrile state with body temperature \> 37.8°c * total bilirubinaemia level is equal or excess 100 μmol / l of the indication of phototherapy. * patient whose jaundice is due to haemolysis, obstruction functional or anatomical. * minor relative * newborn requiring exchange transfusion * newborn with congenital erythropoietic porphyria or a family history of porphyria. * patient requiring treatment other than phototherapy

Keywords: jaundice phototherapy medical device newborn
electrostimulation system woundel for leg ulcers healing (

Conditions: Leg Ulcer; Electrical Remodeling

Summary: several studies have suggested that the endogenous electric field and its polarity stimulate the proliferation and migration of epithelial cells and therefore promote wound healing. woundel® will reproduce the endogenous electrical current to stimulate all the factors contributing to healing. electrostimulation of wounds, including the woundel® device, is a therapy listed but not yet reimbursed in france. the aim of this study is to show that the woundel® electrostimulation device is superior to the reference treatments recognized by the has.

patients with a leg ulcer will be randomized to the "usual treatment" or "woundel" group. the progress of the leg ulcer will be monitored every 2 weeks for 8 weeks or sooner if wound healing occurs. all leg ulcers will be examined at 10 weeks to check for healing or the condition of the leg ulcer if it has not healed. a third-blind party will also assess the ulcer condition at 10 weeks, based on standardized photographs. the consumption of analgesics, pain and quality of life will be compared in the 2 groups.

Eligibility criteria:
inclusion criteria: * venous leg ulcer evolving for at least 3 months, the area of which is between 4 cm² and 200 cm² and the smallest axis of which is less than 10 cm and the largest axis less than 20 cm; * have a systolic pressure index (ips) at the ankle between 0.89 and 1.3 and / or a systolic pressure measurement at the big toe greater than or equal to 60 mmhg; * accept the port of venous compression; * presenting superficial and / or deep venous insufficiency, documented on a doppler echo dating less than one year; * affiliated to a social security scheme or beneficiary of such a scheme; * having given their free, informed and written consent. exclusion criteria: * untreated infected wound; * cancerous ulcer; * treated with systemic corticosteroids or chemotherapy; * for which a skin graft is necessary; * contraindications for the treatment of leg ulcers with the woundel system; * pregnant or lactating women; * vulnerable people or under legal/judicial protection

Keywords: woundel
conducting annual asthma reviews using telehealthcare: comparison with standard care (face-to-face consultations)

Conditions: Asthma

Summary: the national report of asthma deaths published in 2014 highlighted significant deficiencies in both primary and secondary care resulting in one of the highest mortality rates in europe. a key recommendation in the report is the provision of an annual asthma review in primary care. telehealthcare is an alternative means of service delivery incorporating the use of telephone and e-mail consultations which may improve access and quality of patient care. there is scant data on the role of teleheathcare in asthma care. this is a single-centre, primary care-based, randomized controlled trial to evaluate the use of telehealthcare to conduct the annual asthma review for adult patients with well-controlled asthma. this will be compared with standard care (face-to-face consultations). telehealthcare will consist of a telephone consultation followed by an e-mail with an attached personalised asthma action plan and a link to a video demonstrating inhaler technique. standard care will involve a face-to-face consultation in primary care. the two patient groups will be compared prospectively to determine whether there is a difference in the quality of care evaluated in terms of the patient experience/ satisfaction, health-related quality of life, asthma control and frequency of asthma exacerbations over a 6 month period after the asthma review. the data will be presented in the form of frequency tables, bar charts and pie charts. non-parametric tests will be applied to determine whether there is a significant difference in the quality of care received.


Eligibility criteria:
inclusion criteria: * patients aged 18 and over, registered at balham park surgery * patients diagnosed with asthma (patients on the asthma register) * patients with well-controlled asthma (act score 20 and over; no out of hours/ a\&e attendances/ po steroids/ hospital admissions since the last asthma review in primary care) exclusion criteria: * patients aged less than 18 * patients with poorly controlled asthma (act score 19 or less; out of hours/ a\&e attendance/ hospital admission/ po steroids since last asthma review in primary care) * patients with a mental health diagnosis * patients without an up to date contact telephone number or with communication difficulties that would prevent or restrict their use of the technology.

Keywords: telehealthcare
tranexamic acid in patients undergoing total hip arthroplasty in a brazilian reference orthopedic center: a randomized controlled trial

Conditions: Blood Loss, Surgical; Tranexamic Acid Adverse Reaction; Hip Replacement

Summary: this study aims to analyze the efficacy of intravenous tranexamic acid (txa) in patients undergoing total hip arthroplasty (tha).

this was a prospective, experimental, randomized, controlled study of 308 consecutive patients who underwent primary tha from december 2013 to march 2014. 256 volunteers remained in the study, 128 were treated 15 mg/kg intravenous bolus of txa and 128 did not receive the medication. participants were followed up at 3 weeks, 3 months, 6 months, 1 year, and then annually after surgery. the use of txa resulted in lesser reduction in hemoglobin and hematocrit levels, reduced blood loss, blood transfusion rate, volume of blood products, and stay length even in risk factor patients. txa protects risk factor patients against intra and postoperative bleeding and reduces transfusion rates.

Eligibility criteria:
inclusion criteria: * consecutive patients who need total hip replacement were included in the initial sample. there was no age limit or restriction regarding gender for admission to the study. exclusion criteria: * patients who underwent previous surgery in the same joint, evidence of joint infection, congenital or acquired coagulopathies, active intravascular coagulation, acute occlusive vasculopathy, hypersensitivity to txa, chronic use of oral and steroid anticoagulants, history of severe or moderate allergy to plasma transfusion, chronic heart disease, malignant neoplasms and autoimmune diseases, patients who needed bone graft or underwent hip arthroplasty revision surgeries, and who did not consent to participate in the study

Keywords: tranexamic acid blood loss tranfusion